Sessions

Changing the Cell Therapy Landscape with In-Vivo Therapies: Is this a Viable Alternative for Point of Care Therapeutics?
Achieving Best Practice in Quality Control and Assurance
Implementing New and Enabling Technologies into Existing Processes for Improved Commercial Outcomes
Implementing New and Enabling Technologies into Existing Processes for Improved Commercial Outcomes
Analytics, Data and IT Tech Solutions: An Overview of Best Practices and Technology
Delivery Solutions, Improvements and Alternatives for Gene & Cell Therapy
Industry 4.0 Approaches Transforming Cell and Gene Therapy
Accelerating the Digitalisation Revolution in Cell and Gene Therapy Development
Viral Vector Development: Safe and Effective Viral Vectors for Therapeutic Success

Changing the Cell Therapy Landscape with In-Vivo Therapies: Is this a Viable Alternative for Point of Care Therapeutics?

28 Jan 2022
09:00
SPONSORED BY
Humacyte

09:00 Chairperson’s Opening
David Peritt, Founder & Chief Scientific Officer, Lupagen

09:05 Retooling Your Immune System In Vivo to Fight Cancer

  • The emergence of chimeric antigen receptor (CAR) T cells as a therapeutic modality to treat refractory B-cell malignancies has inspired a wave of investment in cell-based immunotherapies.
  • However, the field remains hindered by technical, logistical, consistency, cost, and efficacy limitations associated with autologous and allogeneic manufacturing.
  • To overcome these challenges, Umoja is developing several integrated platforms, one of which is VivoVec, an in vivo CAR engineering platform which uses a unique vector envelope to facilitate transduction of T cells in vivo

David Fontana, Chief Strategy and Business Officer, Umoja-BioPharma

09:20 Bioengineering and the Future of Cardiac Surgery

  • Description of the Human Acellular Vessel (HAV) technology and platform
  • Preclinical advancements in developing a model in coronary artery bypass grafting (CABG) to evaluate the HAV
  • Potential future applications of the HAV in small diameter cardiovascular applications and other clinical populations

Alan Kypson, Cardiac Surgeon, REX Hospital/UNC

09:35 Flexible, Modular, and Post-infusion Controllable CAR-Immune Cell Therapies

  • The OmniCAR platform is the only covalent CAR-Immune cell therapy platform in development
  • OmniCAR enables dose titratable CAR-Activity for safety/efficacy, the ability to turn CAR activity On or OFF,  in-vivo antigen target re-direction, and the ability to multi-arm immune cells
  • Through an ecosystem of off the shelf binders and cells, truly rapid and fully personalized Adoptive Cell Therapy is now possible

Daniel Shelly, Vice President, Prescient Therapeutics

09:50 Bioprinted Cell Therapies as Medicines of the Future

  • Cells, tissues, and organ systems created in the lab will become the next generation of therapeutics
  • Implantable, living tissues are created by combining 3D printing, material science, and biology
  • These living tissues, referred to as ‘bioprinted cell therapies’, are rationally designed to replace or repair damaged biological function

Tamer Mohamed, President & CEO, Aspect Biosystems

10:05 Speaker Q&A and Panel Discussion

Speakers

David Peritt
Founder & Chief Scientific Officer
Lupagen
David Fontana
Chief Business and Strategy Officer
Umoja Biopharma
Alan P Kypson
Cardiac Sugeon
REX Hospital
Daniel Shelly
Vice President
Prescient Therapeutics
Tamer Mohamed
President & Chief Executive Officer
Aspect Biosystems